These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10404355)

  • 1. Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure.
    Cohn JN; Tognoni G; Glazer RD; Spormann D; Hester A
    J Card Fail; 1999 Jun; 5(2):155-60. PubMed ID: 10404355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
    Maggioni AP; Anand I; Gottlieb SO; Latini R; Tognoni G; Cohn JN;
    J Am Coll Cardiol; 2002 Oct; 40(8):1414-21. PubMed ID: 12392830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Cohn JN; Tognoni G;
    N Engl J Med; 2001 Dec; 345(23):1667-75. PubMed ID: 11759645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Hollenberg NK
    Curr Hypertens Rep; 2002 Dec; 4(6):411; discussion 412. PubMed ID: 12462208
    [No Abstract]   [Full Text] [Related]  

  • 6. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA
    Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Tepper D
    Congest Heart Fail; 2002; 8(1):57-8. PubMed ID: 11821630
    [No Abstract]   [Full Text] [Related]  

  • 9. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design.
    Pfeffer MA; McMurray J; Leizorovicz A; Maggioni AP; Rouleau JL; Van De Werf F; Henis M; Neuhart E; Gallo P; Edwards S; Sellers MA; Velazquez E; Califf R
    Am Heart J; 2000 Nov; 140(5):727-50. PubMed ID: 11054617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The benefits of valsartan in the treatment of heart failure: results from Val-HeFT.
    Tan LB; Schlosshan D; Williams SG
    Int J Clin Pract; 2004 Feb; 58(2):184-91. PubMed ID: 15055867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
    Baruch L; Anand I; Cohen IS; Ziesche S; Judd D; Cohn JN
    Circulation; 1999 May; 99(20):2658-64. PubMed ID: 10338459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valsartan for the treatment of heart failure.
    Latini R; Masson S; Staszewsky L; Maggioni AP
    Expert Opin Pharmacother; 2004 Jan; 5(1):181-93. PubMed ID: 14680446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving outcomes in congestive heart failure: Val-HeFT. Valsartan in Heart Failure Trial.
    Cohn JN
    Cardiology; 1999; 91 Suppl 1():19-22. PubMed ID: 10449891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.
    Wong M; Staszewsky L; Latini R; Barlera S; Volpi A; Chiang YT; Benza RL; Gottlieb SO; Kleemann TD; Rosconi F; Vandervoort PM; Cohn JN;
    J Am Coll Cardiol; 2002 Sep; 40(5):970-5. PubMed ID: 12225725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).
    Latini R; Masson S; Anand I; Judd D; Maggioni AP; Chiang YT; Bevilacqua M; Salio M; Cardano P; Dunselman PH; Holwerda NJ; Tognoni G; Cohn JN;
    Circulation; 2002 Nov; 106(19):2454-8. PubMed ID: 12417542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical study of the month. Effects of valsartan in chronic heart failure: the VAL-HeFT study].
    Piérard L
    Rev Med Liege; 2002 Jan; 57(1):57-9. PubMed ID: 11899501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JIKEI HEART Study--a morbi-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease.
    Mochizuki S; Shimizu M; Taniguchi I; Kanae K; Yoshida S; Tajima N; Dahlöf B;
    Cardiovasc Drugs Ther; 2004 Jul; 18(4):305-9. PubMed ID: 15367828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
    Pfeffer MA; McMurray JJ; Velazquez EJ; Rouleau JL; Køber L; Maggioni AP; Solomon SD; Swedberg K; Van de Werf F; White H; Leimberger JD; Henis M; Edwards S; Zelenkofske S; Sellers MA; Califf RM;
    N Engl J Med; 2003 Nov; 349(20):1893-906. PubMed ID: 14610160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of Sadko-CHF study)].
    Skvortsov AA; Mareev VIu; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Masenko VP; Belenkov IuN
    Ter Arkh; 2006; 78(8):14-20. PubMed ID: 17078211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect of monotherapy (data from the trial SADKO-CHF)].
    Skvortsov AA; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Mareev VIu; Belenkov IuN
    Ter Arkh; 2005; 77(8):34-43. PubMed ID: 16206603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.